JP2024138397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024138397A5 JP2024138397A5 JP2024110442A JP2024110442A JP2024138397A5 JP 2024138397 A5 JP2024138397 A5 JP 2024138397A5 JP 2024110442 A JP2024110442 A JP 2024110442A JP 2024110442 A JP2024110442 A JP 2024110442A JP 2024138397 A5 JP2024138397 A5 JP 2024138397A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- aat
- igg
- dimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 46
- 229920001184 polypeptide Polymers 0.000 claims 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims 40
- 229940027941 immunoglobulin g Drugs 0.000 claims 31
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 30
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 30
- 108020001507 fusion proteins Proteins 0.000 claims 28
- 102000037865 fusion proteins Human genes 0.000 claims 28
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 14
- 239000000539 dimer Substances 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102220516587 Kynurenine-oxoglutarate transaminase 1_T256E_mutation Human genes 0.000 claims 3
- 102220053319 rs139287714 Human genes 0.000 claims 3
- 102220325920 rs746060028 Human genes 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502055P | 2011-06-28 | 2011-06-28 | |
| US61/502,055 | 2011-06-28 | ||
| US201161570394P | 2011-12-14 | 2011-12-14 | |
| US61/570,394 | 2011-12-14 | ||
| US201161577204P | 2011-12-19 | 2011-12-19 | |
| US61/577,204 | 2011-12-19 | ||
| US201261638168P | 2012-04-25 | 2012-04-25 | |
| US61/638,168 | 2012-04-25 | ||
| JP2020018783A JP2020078325A (ja) | 2011-06-28 | 2020-02-06 | セルピン融合ポリペプチド及びその使用方法 |
| JP2022069976A JP2022109968A (ja) | 2011-06-28 | 2022-04-21 | セルピン融合ポリペプチド及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069976A Division JP2022109968A (ja) | 2011-06-28 | 2022-04-21 | セルピン融合ポリペプチド及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024138397A JP2024138397A (ja) | 2024-10-08 |
| JP2024138397A5 true JP2024138397A5 (enExample) | 2025-04-14 |
Family
ID=47424806
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519049A Pending JP2014523900A (ja) | 2011-06-28 | 2012-06-28 | セルピン融合ポリペプチド及びその使用方法 |
| JP2017134043A Active JP6674604B2 (ja) | 2011-06-28 | 2017-07-07 | セルピン融合ポリペプチド及びその使用方法 |
| JP2020018783A Pending JP2020078325A (ja) | 2011-06-28 | 2020-02-06 | セルピン融合ポリペプチド及びその使用方法 |
| JP2022069976A Pending JP2022109968A (ja) | 2011-06-28 | 2022-04-21 | セルピン融合ポリペプチド及びその使用方法 |
| JP2024110442A Pending JP2024138397A (ja) | 2011-06-28 | 2024-07-09 | セルピン融合ポリペプチド及びその使用方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519049A Pending JP2014523900A (ja) | 2011-06-28 | 2012-06-28 | セルピン融合ポリペプチド及びその使用方法 |
| JP2017134043A Active JP6674604B2 (ja) | 2011-06-28 | 2017-07-07 | セルピン融合ポリペプチド及びその使用方法 |
| JP2020018783A Pending JP2020078325A (ja) | 2011-06-28 | 2020-02-06 | セルピン融合ポリペプチド及びその使用方法 |
| JP2022069976A Pending JP2022109968A (ja) | 2011-06-28 | 2022-04-21 | セルピン融合ポリペプチド及びその使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US8980266B2 (enExample) |
| EP (2) | EP2726092B1 (enExample) |
| JP (5) | JP2014523900A (enExample) |
| KR (6) | KR20220003656A (enExample) |
| CN (3) | CN103917563A (enExample) |
| AU (4) | AU2012275287B2 (enExample) |
| BR (1) | BR112013033799A2 (enExample) |
| CA (2) | CA3132298A1 (enExample) |
| CY (1) | CY1122195T1 (enExample) |
| DK (1) | DK2726092T3 (enExample) |
| ES (1) | ES2746052T3 (enExample) |
| HR (1) | HRP20191652T1 (enExample) |
| HU (1) | HUE046156T2 (enExample) |
| IL (3) | IL312872A (enExample) |
| IN (1) | IN2013MN02441A (enExample) |
| LT (1) | LT2726092T (enExample) |
| ME (1) | ME03473B (enExample) |
| MX (2) | MX356517B (enExample) |
| NZ (1) | NZ744257A (enExample) |
| PL (1) | PL2726092T3 (enExample) |
| PT (1) | PT2726092T (enExample) |
| RS (1) | RS59368B1 (enExample) |
| RU (4) | RU2727452C1 (enExample) |
| SG (2) | SG10201811256QA (enExample) |
| SI (1) | SI2726092T1 (enExample) |
| SM (1) | SMT201900520T1 (enExample) |
| UA (1) | UA124083C2 (enExample) |
| WO (1) | WO2013003641A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| UA124083C2 (uk) * | 2011-06-28 | 2021-07-21 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
| BR112013033801A2 (pt) * | 2011-06-28 | 2017-12-19 | Inhibrx Llc | proteína de fusão isolada, e, método para tratar ou aliviar um sintoma de uma doença ou distúrbio inflamatórios |
| US10478508B2 (en) * | 2012-01-10 | 2019-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| KR101509020B1 (ko) * | 2013-05-22 | 2015-04-14 | (주)입디 | 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도 |
| WO2015191892A2 (en) | 2014-06-11 | 2015-12-17 | Beth Israel Deaconess Medical Center, Inc. | α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES |
| EP3709019A1 (en) * | 2014-07-23 | 2020-09-16 | Inova Diagnostics, Inc. | Compositions and methods for the diagnosis of rheumatoid arthritis |
| NZ769391A (en) * | 2014-10-27 | 2024-12-20 | Sanofi Aatd Inc | Serpin fusion polypeptides and methods of use thereof |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| US11422719B2 (en) * | 2016-09-15 | 2022-08-23 | Pure Storage, Inc. | Distributed file deletion and truncation |
| US12031144B2 (en) * | 2017-03-29 | 2024-07-09 | Cornell University | Oxidation-resistant AAT gene therapy |
| CA3070303A1 (en) * | 2017-07-27 | 2019-01-31 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| PL3716998T3 (pl) | 2017-12-01 | 2024-06-24 | Csl Behring Llc | A1AT w celu zmniejszenia ryzyka wystąpienia ostrej choroby przeszczep przeciwko gospodarzowi po przeszczepie komórek krwiotwórczych |
| KR20210111245A (ko) * | 2018-10-29 | 2021-09-10 | 스핀 테라퓨틱스, 엘엘씨 | 알파-1-항트립신 장애들을 위한 조성물들 및 방법들 |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
| CA3145702A1 (en) * | 2019-08-01 | 2021-02-04 | Philip A. Pemberton | Oxidation-resistant serpins |
| WO2021102176A2 (en) * | 2019-11-21 | 2021-05-27 | The Regents Of The University Of Michigan | Polypeptide inhibitors of neutrophil elastase activity and uses thereof |
| CN110964094B (zh) * | 2019-12-20 | 2021-11-02 | 华中科技大学 | 人源白细胞蛋白酶抑制因子及其重组制备与应用 |
| CN112341538A (zh) * | 2020-10-27 | 2021-02-09 | 苏州复融生物技术有限公司 | 一种Fc单体多肽及其应用 |
| CA3206022A1 (en) * | 2021-01-26 | 2022-08-04 | Traian Sulea | Ace2-receptor ectodomain fusion molecules and uses thereof |
| GB202102258D0 (en) | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| US20250049898A1 (en) * | 2021-12-22 | 2025-02-13 | The Regents Of The University Of California | Compositions and methods for wound healing |
| EP4526331A1 (en) | 2022-05-16 | 2025-03-26 | Sanofi AATD Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
| CN115466323B (zh) * | 2022-09-13 | 2025-07-01 | 宁波博睿瀚达生物科技有限公司 | 一种分离分泌性白细胞蛋白酶抑制因子的方法 |
| EP4483951A1 (en) * | 2023-06-30 | 2025-01-01 | Université de Liège | Single-domain antibody for inhibition of neutrophil elastase activity |
| WO2025083294A2 (en) | 2024-02-29 | 2025-04-24 | Ageronix SA | Aat-fc fusion protein |
| WO2025219443A1 (en) | 2024-04-19 | 2025-10-23 | Uniqure Biopharma B.V. | Nucleic acid for a1at regulation |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| US5734014A (en) * | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU3609300A (en) * | 1999-03-01 | 2000-09-21 | Human Genome Sciences, Inc. | Human serpin proteins |
| US6849605B1 (en) * | 1999-03-05 | 2005-02-01 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| CA2373721C (en) | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
| CA2392693A1 (en) | 1999-12-01 | 2001-06-07 | Human Genome Sciences, Inc. | Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| FR2814957B1 (fr) | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| AU2002212606A1 (en) * | 2000-11-08 | 2002-05-21 | Prometic Biosciences Inc | Method for the treatment of inflammation |
| DK1355942T3 (da) | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| WO2002050287A2 (en) * | 2000-12-18 | 2002-06-27 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| US7247704B2 (en) * | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| CA2440582A1 (en) * | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1415664A1 (en) * | 2002-10-30 | 2004-05-06 | Switch Biotech Aktiengesellschaft | Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds |
| US7427595B1 (en) * | 2002-12-12 | 2008-09-23 | Cornell Research Foundation, Inc. | Use of proepithelin to promote wound repair and reduce inflammation |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
| US7850970B2 (en) * | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| BRPI0406606A (pt) * | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| JP2007528409A (ja) * | 2004-03-09 | 2007-10-11 | アリバ ファーマシューティカルズ， インコーポレイテッド | プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| MX2007001559A (es) | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| US7399746B2 (en) | 2004-10-06 | 2008-07-15 | Mcgill University | Agents for wound healing |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| AU2006236439B2 (en) * | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| EP1889908A4 (en) | 2005-06-03 | 2012-04-25 | Mochida Pharm Co Ltd | PROTEIN FUSED WITH ANTI-CD14 ANTIBODY |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| EP1926747A1 (en) | 2005-08-12 | 2008-06-04 | Schering Corporation | Mcp1 fusions |
| EA201692543A1 (ru) * | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| CA2647246C (en) | 2006-03-30 | 2015-06-23 | Research Foundation Of City University Of New York | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| BRPI0716139A2 (pt) | 2006-08-28 | 2013-09-17 | Ares Trading Sa | processo para purificaÇço de proteÍnas de fusço fc |
| US20110020269A1 (en) | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| EP3176264B1 (en) * | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| US8598315B2 (en) * | 2007-10-02 | 2013-12-03 | Research Foundation Of City University Of New York | Protein transduction domains derived from secretory leukocyte protease inhibitor |
| AR064713A1 (es) | 2007-12-28 | 2009-04-22 | Consejo Nac Invest Cient Tec | Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| KR101200659B1 (ko) * | 2008-07-23 | 2012-11-12 | 한미사이언스 주식회사 | 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체 |
| RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
| CN102369021B (zh) | 2008-12-19 | 2016-09-07 | 宏观基因有限公司 | 共价双抗体及其用途 |
| EP2417163B1 (en) | 2009-04-10 | 2019-02-27 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| EP2423233B1 (en) * | 2009-04-22 | 2015-03-11 | Alteogen, Inc | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same |
| SE533763C2 (sv) | 2009-05-04 | 2010-12-28 | Lars Hammar | Upphängningsanordning |
| US9035129B2 (en) | 2009-07-08 | 2015-05-19 | The Curators Of The University Of Missouri | Method to develop high oleic acid soybeans using conventional soybean breeding techniques |
| US8614183B2 (en) | 2009-11-13 | 2013-12-24 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| GB201003559D0 (en) | 2010-03-03 | 2010-04-21 | Proteo Biotech Ag | Novel use of elafin |
| EP2588140A4 (en) | 2010-06-30 | 2015-07-15 | Univ Maryland | DENTAL COMPOSITES COMPRISING AMORPHOUS CALCIUM PHOSPHATE NANOPARTICLES |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| BR112013033801A2 (pt) | 2011-06-28 | 2017-12-19 | Inhibrx Llc | proteína de fusão isolada, e, método para tratar ou aliviar um sintoma de uma doença ou distúrbio inflamatórios |
| UA124083C2 (uk) | 2011-06-28 | 2021-07-21 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
| WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
| US10478508B2 (en) | 2012-01-10 | 2019-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| WO2013192131A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| KR20150030744A (ko) | 2012-06-27 | 2015-03-20 | 에프. 호프만-라 로슈 아게 | 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도 |
| KR20150038511A (ko) | 2012-08-02 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 불활성 면역글로불린 Ｆｃ-영역을 갖는 Ｆｃ-융합체로서의 가용성 ＦｃＲ 의 생산 방법 및 그의 용도 |
| CA3138788A1 (en) | 2012-12-05 | 2014-06-12 | Sola Biosciences Llc | Protein expression enhancing polypeptides |
| CN203917563U (zh) | 2014-03-27 | 2014-11-05 | 陈广煌 | 一种切角模具 |
| WO2015191892A2 (en) * | 2014-06-11 | 2015-12-17 | Beth Israel Deaconess Medical Center, Inc. | α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES |
-
2012
- 2012-06-28 UA UAA201400709A patent/UA124083C2/uk unknown
- 2012-06-28 DK DK12804863.4T patent/DK2726092T3/da active
- 2012-06-28 NZ NZ744257A patent/NZ744257A/en unknown
- 2012-06-28 MX MX2013015323A patent/MX356517B/es active IP Right Grant
- 2012-06-28 AU AU2012275287A patent/AU2012275287B2/en active Active
- 2012-06-28 KR KR1020217043197A patent/KR20220003656A/ko not_active Ceased
- 2012-06-28 KR KR1020207005907A patent/KR102231139B1/ko active Active
- 2012-06-28 SG SG10201811256QA patent/SG10201811256QA/en unknown
- 2012-06-28 PL PL12804863T patent/PL2726092T3/pl unknown
- 2012-06-28 IL IL312872A patent/IL312872A/en unknown
- 2012-06-28 ES ES12804863T patent/ES2746052T3/es active Active
- 2012-06-28 EP EP12804863.4A patent/EP2726092B1/en active Active
- 2012-06-28 RU RU2019121797A patent/RU2727452C1/ru active
- 2012-06-28 CN CN201280041956.5A patent/CN103917563A/zh active Pending
- 2012-06-28 HR HRP20191652 patent/HRP20191652T1/hr unknown
- 2012-06-28 EP EP19181040.7A patent/EP3569243A1/en active Pending
- 2012-06-28 MX MX2018006710A patent/MX381183B/es unknown
- 2012-06-28 CN CN201910871347.6A patent/CN110551223A/zh active Pending
- 2012-06-28 US US13/536,976 patent/US8980266B2/en active Active
- 2012-06-28 HU HUE12804863A patent/HUE046156T2/hu unknown
- 2012-06-28 RS RSP20191200 patent/RS59368B1/sr unknown
- 2012-06-28 LT LTEP12804863.4T patent/LT2726092T/lt unknown
- 2012-06-28 PT PT128048634T patent/PT2726092T/pt unknown
- 2012-06-28 CN CN201910132137.5A patent/CN110066340B/zh active Active
- 2012-06-28 BR BR112013033799A patent/BR112013033799A2/pt not_active Application Discontinuation
- 2012-06-28 SG SG10201601621PA patent/SG10201601621PA/en unknown
- 2012-06-28 WO PCT/US2012/044730 patent/WO2013003641A2/en not_active Ceased
- 2012-06-28 CA CA3132298A patent/CA3132298A1/en active Pending
- 2012-06-28 RU RU2017145308A patent/RU2698655C2/ru active
- 2012-06-28 KR KR1020147002346A patent/KR102084944B1/ko active Active
- 2012-06-28 KR KR1020217007901A patent/KR20210032558A/ko not_active Ceased
- 2012-06-28 IN IN2441MUN2013 patent/IN2013MN02441A/en unknown
- 2012-06-28 SM SM20190520T patent/SMT201900520T1/it unknown
- 2012-06-28 JP JP2014519049A patent/JP2014523900A/ja active Pending
- 2012-06-28 KR KR1020237024532A patent/KR102756547B1/ko active Active
- 2012-06-28 ME MEP-2019-253A patent/ME03473B/me unknown
- 2012-06-28 SI SI201231670T patent/SI2726092T1/sl unknown
- 2012-06-28 CA CA2839619A patent/CA2839619C/en active Active
- 2012-06-28 RU RU2014102583A patent/RU2642310C2/ru active
- 2012-06-28 KR KR1020257001261A patent/KR20250012200A/ko active Pending
-
2013
- 2013-08-19 US US13/969,959 patent/US9920109B2/en active Active
- 2013-12-26 IL IL230209A patent/IL230209B/en active IP Right Grant
-
2015
- 2015-02-06 US US14/616,363 patent/US10730929B2/en active Active
-
2017
- 2017-07-07 JP JP2017134043A patent/JP6674604B2/ja active Active
- 2017-12-21 AU AU2017279724A patent/AU2017279724B2/en active Active
-
2018
- 2018-01-19 US US15/875,010 patent/US10723785B2/en active Active
-
2019
- 2019-04-24 US US16/393,619 patent/US20200102371A1/en not_active Abandoned
- 2019-04-24 AU AU2019202904A patent/AU2019202904B2/en active Active
- 2019-07-11 RU RU2019121798A patent/RU2728861C1/ru active
- 2019-09-18 CY CY20191100993T patent/CY1122195T1/el unknown
-
2020
- 2020-02-06 JP JP2020018783A patent/JP2020078325A/ja active Pending
- 2020-06-22 US US16/908,271 patent/US11827691B2/en active Active
- 2020-08-05 IL IL276534A patent/IL276534B2/en unknown
- 2020-10-08 US US17/066,410 patent/US11965017B2/en active Active
-
2021
- 2021-04-07 AU AU2021202131A patent/AU2021202131B2/en active Active
-
2022
- 2022-04-21 JP JP2022069976A patent/JP2022109968A/ja active Pending
-
2024
- 2024-03-13 US US18/604,420 patent/US20250011394A1/en active Pending
- 2024-07-09 JP JP2024110442A patent/JP2024138397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024138397A5 (enExample) | ||
| JP6923115B2 (ja) | 高グリコシル化ヒト血液凝固第ｖｉｉｉ因子の融合タンパク質、その調製方法、および使用 | |
| JP2022043042A5 (enExample) | ||
| RU2017145308A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| CA3059994C (en) | Human coagulation factor ix (fix) fusion protein, preparation method therefor, and use thereof | |
| JP2017537888A5 (enExample) | ||
| AU2012275295B2 (en) | WAP domain fusion polypeptides and methods of use thereof | |
| JP2025114622A5 (enExample) | ||
| JP7731288B2 (ja) | アルファ－１－アンチトリプシン欠乏症のための組成物及び方法 | |
| JPS63503357A (ja) | 新規な凝固活性タンパク質 | |
| JPH04507252A (ja) | 抗凝血タンパク質 | |
| JP2004528014A5 (enExample) | ||
| JP2007500744A5 (enExample) | ||
| RU2017118325A (ru) | Слитые серпиновые полипептиды и способы их применения | |
| JP2653247B2 (ja) | 新規エラフィン誘導体 | |
| CN112673026B (zh) | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 | |
| WO2003062370B1 (en) | Multimeric proteins and methods of making and using same | |
| JP2005522192A5 (enExample) | ||
| JPWO1994004697A1 (ja) | 新規エラフィン誘導体 | |
| JPWO2021116182A5 (enExample) | ||
| JPWO2021226551A5 (enExample) | ||
| JPWO2020092448A5 (enExample) | ||
| JPS61108397A (ja) | インタ−フエロン−γ蛋白質の製造法 | |
| JPH05213998A (ja) | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 | |
| JP2561122B2 (ja) | 機能性ポリペプチド |